WO2026046292A1 - Composition pharmaceutique d'inhibiteur peptidique du récepteur de l'interleukine-23, son procédé de préparation et son utilisation - Google Patents

Composition pharmaceutique d'inhibiteur peptidique du récepteur de l'interleukine-23, son procédé de préparation et son utilisation

Info

Publication number
WO2026046292A1
WO2026046292A1 PCT/CN2025/117542 CN2025117542W WO2026046292A1 WO 2026046292 A1 WO2026046292 A1 WO 2026046292A1 CN 2025117542 W CN2025117542 W CN 2025117542W WO 2026046292 A1 WO2026046292 A1 WO 2026046292A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
analogues
pharmaceutical composition
pharmaceutical
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/CN2025/117542
Other languages
English (en)
Chinese (zh)
Inventor
李小平
傅灵
关琳
任东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tibet Haisco Pharmaceutical Co Ltd
Original Assignee
Tibet Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibet Haisco Pharmaceutical Co Ltd filed Critical Tibet Haisco Pharmaceutical Co Ltd
Publication of WO2026046292A1 publication Critical patent/WO2026046292A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention se rapporte au domaine des formulations pharmaceutiques, et concerne en particulier une composition pharmaceutique ou une formulation pharmaceutique formulée sous forme de dose unique. La composition pharmaceutique ou la formulation pharmaceutique comprend un principe actif M et un excipient pharmaceutiquement acceptable. Le principe actif M est choisi parmi un composé peptidique cyclique, un stéréoisomère de celui-ci, un sel pharmaceutiquement acceptable de celui-ci, un solvate de celui-ci, ou un dimère de celui-ci, le composé peptidique ayant une séquence d'acides aminés représentée par la formule (I) : Xa1-Xa2-Xa3-Xa4-Xa5-Xa6-Xa7-Xa8-Xa9-Xa10-Xa11-Xa12-Xa13 (I). La composition pharmaceutique ou la formulation pharmaceutique comprend de 1 mg à 1000 mg du principe actif M, sur la base du contenu d'une forme de base libre. La présente invention concerne également l'utilisation de la composition pharmaceutique ou de la formulation pharmaceutique dans la préparation d'un médicament pour la prévention et le traitement d'une maladie ou d'un trouble surexprimant l'IL-23 dans un tissu malade d'un sujet.
PCT/CN2025/117542 2024-08-28 2025-08-28 Composition pharmaceutique d'inhibiteur peptidique du récepteur de l'interleukine-23, son procédé de préparation et son utilisation Pending WO2026046292A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN202411193128 2024-08-28
CN202411193128.4 2024-08-28
CN202411570169.0 2024-11-06
CN202411570169 2024-11-06
CN202510585903.9 2025-05-08
CN202510585903 2025-05-08

Publications (1)

Publication Number Publication Date
WO2026046292A1 true WO2026046292A1 (fr) 2026-03-05

Family

ID=98931351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2025/117542 Pending WO2026046292A1 (fr) 2024-08-28 2025-08-28 Composition pharmaceutique d'inhibiteur peptidique du récepteur de l'interleukine-23, son procédé de préparation et son utilisation

Country Status (1)

Country Link
WO (1) WO2026046292A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115298196A (zh) * 2020-01-15 2022-11-04 詹森生物科技公司 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
CN117999274A (zh) * 2021-07-14 2024-05-07 詹森生物科技公司 白介素-23受体的肽抑制剂
CN118055773A (zh) * 2021-07-14 2024-05-17 詹森生物科技公司 白介素-23受体的脂化肽抑制剂
WO2024155552A1 (fr) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Formulations d'inhibiteurs peptidiques lipidés du récepteur de l'interleukine-23
WO2024227437A1 (fr) * 2023-05-04 2024-11-07 西藏海思科制药有限公司 Préparation d'un inhibiteur peptidique du récepteur de l'interleukine-23 et son utilisation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115298196A (zh) * 2020-01-15 2022-11-04 詹森生物科技公司 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
CN117999274A (zh) * 2021-07-14 2024-05-07 詹森生物科技公司 白介素-23受体的肽抑制剂
CN118055773A (zh) * 2021-07-14 2024-05-17 詹森生物科技公司 白介素-23受体的脂化肽抑制剂
WO2024155552A1 (fr) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Formulations d'inhibiteurs peptidiques lipidés du récepteur de l'interleukine-23
WO2024227437A1 (fr) * 2023-05-04 2024-11-07 西藏海思科制药有限公司 Préparation d'un inhibiteur peptidique du récepteur de l'interleukine-23 et son utilisation

Similar Documents

Publication Publication Date Title
KR20240034223A (ko) 인터류킨-23 수용체의 바이사이클릭 펩티드 억제제
AU2023349260B2 (en) DUAL-TARGETING COMPOUND AGAINST FIBROBLAST ACTIVATION PROTEIN FAP AND INTEGRIN αVβ3, AND PREPARATION METHOD THEREFOR AND USE THEREOF
BR112020004555A2 (pt) agentes que modulam funções de beta-catenina e métodos dos mesmos
EP2836493B1 (fr) Dérivés de thiéno-indole fonctionnalisés pour le traitement du cancer
TW202116356A (zh) 作為治療劑之微管靶向藥劑之肽結合物
CN105658670A (zh) 肽-低聚尿素嵌合化合物及其使用方法
WO2024227437A1 (fr) Préparation d'un inhibiteur peptidique du récepteur de l'interleukine-23 et son utilisation
EP0514131A1 (fr) 2-Benzazépines à cycles hétérocycliques de 5 et 6 côtés
IL263356B (en) A crystalline form of a compound that suppresses protein kinase activity, and its application
JP2001518515A (ja) リウマチ性関節炎の治療組成物および治療方法
WO2026046292A1 (fr) Composition pharmaceutique d'inhibiteur peptidique du récepteur de l'interleukine-23, son procédé de préparation et son utilisation
TW202241892A (zh) 用於治療弗里德希氏運動失調症（ｆｒｉｅｄｒｅｉｃｈ＇ｓ ａｔａｘｉａ）之方法及化合物
WO1997017364A1 (fr) Derives peptidiques de dolastatine-15 et utilisation desdits derives
CN115197202B (zh) 一种ezh2共价抑制剂及其制备方法和应用
AU2021307245B2 (en) Crystal of pyrimidine compound
JP2023537111A (ja) 環状ケメリン－９誘導体
CN121449688A (zh) 白介素-23受体的肽抑制剂及其用途
WO2026026815A1 (fr) Inhibiteur peptidique du récepteur de l'interleukine-23 et son utilisation
CN121021645B (zh) 富含正电荷的μ-芋螺毒素KIIIA的突变体及其应用
WO2026026816A1 (fr) Inhibiteur peptidique du récepteur de l'interleukine-23 et son utilisation
JP2025532958A (ja) ＥｐｈＡ２結合保留ペプチド及びそれを含む組成物
HK40129633A (zh) 苯乙胺和卡西酮及其立体异构体与其前体的制备
WO2002102833A1 (fr) Nouveaux derives d'endomorphine
CN121219306A (zh) 白介素-23受体的肽抑制剂
CN121554539A (zh) 一种具有单二硫键的芋螺多肽及其突变体和应用